^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Small Intestinal Carcinoma

Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
06/13/2024
Initiation :
01/30/2017
Primary completion :
05/01/2026
Completion :
05/01/2026
CD4
|
PD-L1 overexpression • PD-L1 amplification
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/10/2024
Initiation :
10/05/2021
Primary completion :
06/30/2024
Completion :
12/31/2025
PD-L1 • CD4
|
PD-L1 negative
|
Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC
Phase 1/2
Immunitas Therapeutics
Recruiting
Last update posted :
05/03/2024
Initiation :
11/28/2022
Primary completion :
04/01/2025
Completion :
04/01/2025
KRAS • BRAF • ALK • PIK3CA • MET • MSI
|
BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation
|
Fruzaqla (fruquintinib) • IMT-009
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
05/02/2024
Initiation :
02/22/2021
Primary completion :
12/31/2024
Completion :
12/31/2024
MSI • MLH1 • MSH6 • MSH2 • CEACAM5
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • Opdivo (nivolumab)
Phase N/A
George Zogopoulos
Recruiting
Last update posted :
04/17/2024
Initiation :
03/12/2012
Primary completion :
01/01/2025
Completion :
01/01/2025
BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
|
ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
04/16/2024
Initiation :
01/19/2023
Primary completion :
01/31/2026
Completion :
02/21/2026
APC
|
APC mutation
Phase 2
M.D. Anderson Cancer Center
Completed
Last update posted :
04/05/2024
Initiation :
04/07/2017
Primary completion :
04/02/2024
Completion :
04/02/2024
PD-L1
|
PD-L1 expression
|
Tecentriq (atezolizumab) • Cotellic (cobimetinib)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
03/07/2024
Initiation :
02/01/2016
Primary completion :
11/08/2018
Completion :
03/05/2025
CD4
|
ropidoxuridine (IPdR)
Phase 1
City of Hope Medical Center
Active, not recruiting
Last update posted :
01/04/2024
Initiation :
10/08/2013
Primary completion :
01/09/2018
Completion :
09/27/2024
EGFR • CD34
Phase 2
Academic and Community Cancer Research United
Active, not recruiting
Last update posted :
12/28/2023
Initiation :
03/24/2017
Primary completion :
01/31/2019
Completion :
03/31/2024
PD-L1 • MSI
|
Keytruda (pembrolizumab)
Phase N/A
University of California, San Francisco
Recruiting
Last update posted :
11/17/2023
Initiation :
08/07/2020
Primary completion :
12/31/2024
Completion :
11/30/2026
MSI • PD-1
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
11/14/2023
Initiation :
09/22/2020
Primary completion :
10/25/2022
Completion :
01/31/2026
CEACAM5 • CD4
|
bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
Phase N/A
xCures
Available
Last update posted :
08/21/2023
BRAF • NRAS • HRAS • MAPK1
|
BRAF mutation • ER mutation • HRAS mutation
|
ulixertinib (BVD-523)
Phase 1/2
University of Chicago
Active, not recruiting
Last update posted :
04/28/2023
Initiation :
07/29/2014
Primary completion :
07/29/2023
Completion :
07/29/2023
MYC • BCL2 • CD20 • BCL6 • IRF4 • MME
|
BCL2 positive
|
Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • melphalan • cyclophosphamide intravenous
Phase 1/2
Jacobio Pharmaceuticals Co., Ltd.
Recruiting
Last update posted :
03/10/2023
Initiation :
02/17/2022
Primary completion :
12/01/2023
Completion :
01/01/2026
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
Erbitux (cetuximab) • glecirasib (JAB-21822)
Phase N/A
San Raffaele University
Recruiting
Last update posted :
01/30/2023
Initiation :
11/01/2018
Primary completion :
12/31/2025
Completion :
12/31/2026
MLH1 • MSH6 • MSH2 • EPCAM
Phase N/A
University Medicine Greifswald
Completed
Last update posted :
01/24/2023
Initiation :
06/25/2020
Primary completion :
12/06/2022
Completion :
12/06/2022
CRP
Phase N/A
Wake Forest University Health Sciences
Completed
Last update posted :
10/14/2022
Initiation :
08/01/2016
Primary completion :
01/01/2020
Completion :
01/01/2020
IL6 • TNFA • TNFRSF1A
Phase 3
Ruijin Hospital
Recruiting
Last update posted :
05/03/2022
Initiation :
06/15/2020
Primary completion :
10/07/2022
Completion :
11/30/2022
IL6 • CRP
Phase 3
Advanced Accelerator Applications
Completed
Last update posted :
04/04/2022
Initiation :
09/06/2012
Primary completion :
07/31/2015
Completion :
01/18/2021
SSTR
|
Lutathera (lutetium Lu 177 dotatate) • octreotide acetate
Phase 2
M.D. Anderson Cancer Center
Completed
Last update posted :
02/21/2020
Initiation :
11/02/2010
Primary completion :
07/03/2018
Completion :
07/03/2018
KRAS
|
KRAS mutation • KRAS wild-type • RAS wild-type
|
Vectibix (panitumumab)
Phase N/A
Copenhagen University Hospital, Hvidovre
Completed
Last update posted :
02/13/2020
Initiation :
12/01/2017
Primary completion :
01/23/2020
Completion :
01/23/2020
APC
|
APC mutation
Phase 2
Fred Hutchinson Cancer Center
Completed
Last update posted :
01/29/2020
Initiation :
04/01/2004
Primary completion :
03/01/2014
Completion :
07/01/2018
HLA-DRB1 • HLA-B • HLA-C
|
fludarabine IV
Phase 2
M.D. Anderson Cancer Center
Completed
Last update posted :
01/18/2020
Initiation :
11/01/2012
Primary completion :
08/01/2016
Completion :
08/01/2016
KRAS • MLH1
|
KRAS wild-type • RAS wild-type
|
albumin-bound paclitaxel
Phase 2
University of Chicago
Completed
Last update posted :
08/07/2019
Initiation :
04/04/2013
Primary completion :
08/01/2018
Completion :
08/01/2018
HLA-DRB1
Phase N/A
China Medical University, China
Unknown status
Last update posted :
04/16/2019
Initiation :
03/01/2019
Primary completion :
12/01/2019
Completion :
06/01/2020
MSI
|
MSI-H/dMMR
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
07/24/2018
Initiation :
06/01/2013
Primary completion :
03/01/2014
Completion :
03/01/2014
IL6 • HLA-DRB1 • HLA-B • HLA-C
|
Zolinza (vorinostat) • cyclosporin A microemulsion • methotrexate IV
Phase N/A
Ohio State University Comprehensive Cancer Center
Completed
Last update posted :
03/12/2018
Initiation :
12/12/2007
Primary completion :
07/29/2011
Completion :
07/29/2011
ALK • IL10 • TGFB1
|
ALK negative
Phase N/A
Florida Hospital Tampa Bay Division
Enrolling by invitation
Last update posted :
02/07/2018
Initiation :
10/01/2013
Primary completion :
12/01/2018
Completion :
12/01/2022
IL6 • CEACAM5 • IL2 • IL10 • CA 19-9
Phase 2
Fred Hutchinson Cancer Center
Completed
Last update posted :
01/02/2018
Initiation :
02/01/2009
Primary completion :
03/01/2015
Completion :
03/26/2015
CD20
|
CD20 expression
|
Rituxan (rituximab)
Phase 2
Alliance for Clinical Trials in Oncology
Completed
Last update posted :
08/24/2017
Initiation :
05/01/2007
Primary completion :
12/01/2014
Completion :
05/01/2016
UGT1A1
|
UGT1A1*1*1
|
capecitabine • oxaliplatin • irinotecan
Phase 1
Vanderbilt-Ingram Cancer Center
Completed
Last update posted :
07/02/2017
Initiation :
11/01/2009
Primary completion :
07/01/2013
Completion :
10/01/2016
KRAS • CDH1 • VIM
|
erlotinib • gemcitabine • oxaliplatin
Phase 2
Fred Hutchinson Cancer Center
Completed
Last update posted :
05/30/2017
Initiation :
03/01/2005
Primary completion :
07/01/2010
Completion :
05/26/2015
HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
|
Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion
Phase 1
Mayo Clinic
Completed
Last update posted :
05/25/2017
Initiation :
06/01/2008
Primary completion :
11/01/2010
Completion :
12/03/2012
UGT1A1
|
UGT1A1*1*1
|
5-fluorouracil • irinotecan • leucovorin calcium
Phase 2
University of Washington
Completed
Last update posted :
05/24/2017
Initiation :
08/01/2010
Primary completion :
11/01/2013
CD34
|
cisplatin • etoposide IV • dexamethasone • bendamustine • Neupogen (filgrastim)
Phase N/A
Fred Hutchinson Cancer Center
Completed
Last update posted :
05/24/2017
Initiation :
11/01/1999
Primary completion :
11/01/2014
HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B • HLA-C
|
fludarabine IV • cyclosporin A microemulsion
Phase 2
Fred Hutchinson Cancer Center
Completed
Last update posted :
05/19/2017
Initiation :
09/01/2011
Primary completion :
06/01/2014
Completion :
07/01/2015
FLT3 • KIT • NPM1 • HLA-DRB1 • HLA-B • HLA-C
|
MLL rearrangement • MLL rearrangement
|
cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous
Phase 2
Fred Hutchinson Cancer Center
Completed
Last update posted :
05/17/2017
Initiation :
01/01/2002
Primary completion :
03/01/2011
Completion :
02/01/2014
CD8 • HLA-DRB1 • PTPRC • NCAM1 • HLA-B • HLA-C • NCR1
|
CD8 expression • Chr del(5q) • CD4 expression
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous